Edition:
India

Agenus Inc (AGEN.OQ)

AGEN.OQ on NASDAQ Stock Exchange Capital Market

3.59USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.59
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
285,781
52-wk High
$5.44
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Agenus reports Q3 loss per share $0.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Agenus Inc :Agenus reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.37.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Agenus Inc - ‍Cash, cash equivalents and short-term investments were $70.1 million at Sept 30, 2017 compared to $76.4 million as of Dec 31, 2016​.Agenus Inc - Qtrly revenue $3.4 million versus $4.4 mln‍​.  Full Article

Agenus files for mixed shelf of up to $250 million
Thursday, 19 Oct 2017 

Oct 18 (Reuters) - Agenus Inc :Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​.  Full Article

Venbio Select Advisor LLC reports a 5.41 pct passive stake in Agenus
Friday, 10 Feb 2017 

Agenus Inc :Venbio Select Advisor Llc reports a 5.41 passive stake in Agenus Inc as on December 31, 2016 - sec filing.  Full Article

Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine
Tuesday, 17 Jan 2017 

Agenus Inc : Agenus Inc says collaboration with National Cancer Institute to evaluate combination of Pembrolizumab with prophage autologous vaccine .Agenus says under collaboration, Agenus will supply Prophage, Merck will provide pembrolizumab and NCI and BTTC member sites will recruit patients and conduct trial.  Full Article

Agenus Q2 loss per share $0.33
Thursday, 28 Jul 2016 

Agenus Inc : Qtrly revenue $6.6 million versus $6.4 million . Agenus reports second quarter 2016 financial results and operational progress . Q2 loss per share $0.33 . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S .Q2 revenue view $5.1 million -- Thomson Reuters I/B/E/S.  Full Article

Agenus' chief financial officer, C.Evan Ballantyne to resign
Tuesday, 19 Jul 2016 

Agenus Inc : On july 14, 2016, C. Evan Ballantyne, chief financial officer informed agenus of his intention to resign - sec filing .Christin Klaskin, Agenus' VP, finance and principal accounting officer, will retain her roles, assume role of principal financial officer.  Full Article

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
Wednesday, 22 Jun 2016 

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.  Full Article

Agenus Inc acquires PhosImmune
Wednesday, 23 Dec 2015 

Agenus Inc:Acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens.The acquisition provides Agenus the ability to accelerate the development of new cancer vaccines and other single agent immuno-oncology approaches, as well as combination therapies.Under the terms of the agreement, Agenus paid PhosImmune's equity holders an upfront payment of $2.5 million in cash and $7.4 million in shares of Agenus common stock at closing.Additional payments of up to $35 million in cash and/or stock at Agenus' election are payable upon the achievement of certain.  Full Article

BRIEF-Agenus reports Q3 loss per share $0.37

* Agenus reports third quarter 2017 financial results and provides corporate update